How feasible is the stratification of osteoarthritis phenotypes by means of artificial intelligence?

IF 1 Q4 PHARMACOLOGY & PHARMACY Expert Review of Precision Medicine and Drug Development Pub Date : 2021-01-01 Epub Date: 2020-11-23 DOI:10.1080/23808993.2021.1848424
Amanda E Nelson
{"title":"How feasible is the stratification of osteoarthritis phenotypes by means of artificial intelligence?","authors":"Amanda E Nelson","doi":"10.1080/23808993.2021.1848424","DOIUrl":null,"url":null,"abstract":"Osteoarthritis (OA) is a common and serious disease that involves all of the tissues of an affected joint (e.g., cartilage, bone, meniscus, tendon/ligament, synovium) and can affect one or multiple joints in an individual person, most often the finger joints, knees, hips, and spine [1]. OA is a major and growing contributor to disability worldwide and is associated with increased comorbidity and excess mortality [1]. Management of OA is focused on modestly effective lifestyle/behavioral interventions such as increased physical activity and weight loss, with pharmacologic therapies directed toward temporary symptomatic relief [2]. Although many clinical trials have been conducted, there are still no effective disease-modifying therapies, no proven way to prevent progression, and no cure. This is at least in part due to the lack of appreciation of, and accounting for, the heterogeneity of this complex disease in trials to date [3]. In general, most trials have enrolled all individuals with knee OA defined as the presence of symptoms (e.g., pain, aching, and stiffness) and moderate to severe radiographic change (e.g., osteophytes or joint space narrowing) in at least one knee. This does not account for the diverse mechanisms of disease development, which can be due to mechanical dysfunction, prior injury, metabolic factors, inflammation, or combinations of these. Nor does it address the diversity of presentations, burden of disease (i.e., number/severity of involved joints), chronicity, or numerous other aspects of the disease process in a given individual that may subsequently affect their response to the proposed therapy. This brief editorial review seeks to summarize recent work in the area of machine learning and osteoarthritis phenotyping.","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":"6 2","pages":"83-85"},"PeriodicalIF":1.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23808993.2021.1848424","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Precision Medicine and Drug Development","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/23808993.2021.1848424","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/11/23 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 5

Abstract

Osteoarthritis (OA) is a common and serious disease that involves all of the tissues of an affected joint (e.g., cartilage, bone, meniscus, tendon/ligament, synovium) and can affect one or multiple joints in an individual person, most often the finger joints, knees, hips, and spine [1]. OA is a major and growing contributor to disability worldwide and is associated with increased comorbidity and excess mortality [1]. Management of OA is focused on modestly effective lifestyle/behavioral interventions such as increased physical activity and weight loss, with pharmacologic therapies directed toward temporary symptomatic relief [2]. Although many clinical trials have been conducted, there are still no effective disease-modifying therapies, no proven way to prevent progression, and no cure. This is at least in part due to the lack of appreciation of, and accounting for, the heterogeneity of this complex disease in trials to date [3]. In general, most trials have enrolled all individuals with knee OA defined as the presence of symptoms (e.g., pain, aching, and stiffness) and moderate to severe radiographic change (e.g., osteophytes or joint space narrowing) in at least one knee. This does not account for the diverse mechanisms of disease development, which can be due to mechanical dysfunction, prior injury, metabolic factors, inflammation, or combinations of these. Nor does it address the diversity of presentations, burden of disease (i.e., number/severity of involved joints), chronicity, or numerous other aspects of the disease process in a given individual that may subsequently affect their response to the proposed therapy. This brief editorial review seeks to summarize recent work in the area of machine learning and osteoarthritis phenotyping.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
通过人工智能手段对骨关节炎表型进行分层的可行性如何?
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.30
自引率
0.00%
发文量
9
期刊介绍: Expert Review of Precision Medicine and Drug Development publishes primarily review articles covering the development and clinical application of medicine to be used in a personalized therapy setting; in addition, the journal also publishes original research and commentary-style articles. In an era where medicine is recognizing that a one-size-fits-all approach is not always appropriate, it has become necessary to identify patients responsive to treatments and treat patient populations using a tailored approach. Areas covered include: Development and application of drugs targeted to specific genotypes and populations, as well as advanced diagnostic technologies and significant biomarkers that aid in this. Clinical trials and case studies within personalized therapy and drug development. Screening, prediction and prevention of disease, prediction of adverse events, treatment monitoring, effects of metabolomics and microbiomics on treatment. Secondary population research, genome-wide association studies, disease–gene association studies, personal genome technologies. Ethical and cost–benefit issues, the impact to healthcare and business infrastructure, and regulatory issues.
期刊最新文献
The future of precision medicine in oncology Peptide receptor radionuclide therapy in neuroendocrine neoplasms and related tumors: from fundamentals to personalization and the newer experimental approaches Identifying patients suitable for targeted adjuvant therapy: advances in the field of developing biomarkers for tumor recurrence following irradiation. Predictors of response for hepatocellular carcinoma immunotherapy: is there anything on the horizon? Therapeutic potential of GABAA receptor subunit expression abnormalities in fragile X syndrome
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1